SOUTH SAN FRANCISCO, Calif.,
April 30, 2014 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced
that it will host an Investor Day on Tuesday, May 6, 2014 from 9:30 a.m. to 12:00 p.m. E.T. in New York City. Rigel management will provide
an overview of the company's product portfolio and discuss future
strategy.
Donald G. Payan, M.D., executive
vice president and president of discovery and research of Rigel,
will provide an overview of Rigel's product portfolio, including an
outline of its upcoming Phase 3 studies of fostamatinib in patients
with Immune Thrombocytopenic Purpura (ITP).
At the event, James B. Bussel,
M.D., a leading expert on ITP and professor of pediatrics in
medicine, Weill Cornell Medical College, will comment on
fostamatinib and treatment options for ITP.
To access the live audio webcast or the subsequent archived
recording, log on to www.rigel.com. Please connect to Rigel's
website several minutes prior to the start of the live webcast to
ensure adequate time for any software download that may be
necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development
company that discovers and develops novel, small-molecule drugs for
the treatment of inflammatory and autoimmune diseases, as well as
muscle disorders. Rigel's pioneering research focuses on
intracellular signaling pathways and related targets that are
critical to disease mechanisms. Rigel currently has five product
candidates in development: fostamatinib, an oral SYK inhibitor
expected to enter Phase 3 clinical trials for ITP in the second
quarter of 2014 and a Phase 2 clinical trial for IgA nephropathy in
the second half of 2014; R348, a topical JAK/SYK inhibitor
currently in Phase 2 clinical trials for dry eye; R118, an AMPK
activator in Phase 1 development; and two oncology product
candidates in Phase 1 development with partners BerGenBio and
Daiichi Sankyo.
Contacts:
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com
Media Contact: Susan C. Rogers,
Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com
SOURCE Rigel Pharmaceuticals, Inc.